Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $61
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $68 to $61.
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $68 to $61.